[Lipodystrophy and metabolic disorders in anti-HIV therapy] NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Lipodystrophy and metabolic disorders in anti-HIV therapy]

MMW Fortschr Med. 2000 Mar 13;142 Suppl 1:68-71. Unique Identifier : AIDSLINE MED/20321539
Behrens GM; Stoll M; Schmidt RE; Abteilung fur Klinische Immunologie, Medizinische Hochschule; Hannover. Behrens.Georg@MH-Hannover.de


Abstract: For the effective treatment of HIV infection, combinations of antiretroviral drugs that, at various points of attack, prevent viral replication are used. After the introduction of HIV-1 specific protease inhibitors, various metabolic complications and changes in body habitus manifesting as abnormal fat distribution were observed in HIV patients. These side effects, initially assigned class-specifically to the protease inhibitors, have, however, also been frequently seen under other drug combinations. Changes to body habitus as a result of fat redistribution have mostly been designated as lipodystrophy syndrome, but are now increasingly being recognized as highly heterogeneous abnormalities. Furthermore, the disturbances of glucose and fat metabolism may occur completely independently of phenotypic habitus changes. The result is that both the suspected pathophysiological relationships and the therapeutic consequences are becoming even more complex. This paper summarizes the current state of investigations into the side effects of antiretroviral therapy and their clinical consequences.


Keywords: JOURNAL ARTICLE Anti-HIV-Therapie. Anti-HIV Agents/*ADVERSE EFFECTS/THERAPEUTIC USE Diabetes Mellitus/*CHEMICALLY INDUCED English Abstract Human HIV Infections/*DRUG THERAPY/VIROLOGY HIV-1/*DRUG EFFECTS Insulin Resistance Lipodystrophy/*CHEMICALLY INDUCED

KWDjournalarticleanti-hiv-therapieKWDanti-hivagents/KWDadverseeffects/therapeuticusediabetesmellitus/KWDchemicallyinducedenglishabstracthumanhivinfections/KWDdrugtherapy/virologyhiv-1/KWDdrugeffectsinsulinresistancelipodystrophy/KWDchemicallyinduced
001130
A00B1133


Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .